SCHEMBL4284930

SCHEMBL4284930

CC(=O)C(c1nc2ccc(C)cc2s1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.52
ACHE P22303 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
MGLL Q99685 1/20 0.46
CCR1 P32246 1/20 0.44
CCR3 P51677 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LTA4H P09960 2/20 0.43
GAA P10253 1/20 0.43
KCNH2 Q12809 1/20 0.43
CTNNB1 P35222 1/20 0.43
TCF7L2 Q9NQB0 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289984 0.82 BCHE (0.61) BCHEACHESMN1; SMN2ALDH1A1LMNA
SCHEMBL4737226 0.82 GAA (0.44) BCHEACHEDCUN1D1GAATSHR
Hydrochloric Acid SCHEMBL9385815 0.82 BCHE (0.61) BCHEACHESMN1; SMN2ALDH1A1LMNA
SCHEMBL9381131 0.77 ACHE (0.48) BCHEACHESMN1; SMN2ALDH1A1HPGD
SCHEMBL4736492 0.77 MAOB (0.43) ACHEDCUN1D1GAATSHR
SCHEMBL221273 0.76 ACHE (0.70) BCHEACHE
SCHEMBL4284928 0.76 BCHE (0.58) BCHEACHESMN1; SMN2ALDH1A1LMNA
SCHEMBL4284931 0.75 DRD4 (0.45) BCHEACHE
SCHEMBL4790506 0.75 DCUN1D1 (0.44) BCHEACHEDCUN1D1GAATSHR
SCHEMBL9382371 0.74 ITK (0.46) BCHEACHEDCUN1D1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009158646-A1 THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE ELIXIR PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
EP-1898897-A2 METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS Sirtris Pharmaceuticals, Inc. (US) 2008-03-19 EP disclosed
EP-1877054-A2 NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF Sirtris Pharmaceuticals, Inc. (US) 2008-01-16 EP disclosed
EP-1853590-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
WO-2007008548-A2 METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS SIRTRIS PHARMACEUTICALS, INC. (US) 2007-01-18 WO disclosed
WO-2006105440-A2 NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF SIRTRIS PHARMACEUTICALS, INC. (US) 2006-10-05 WO disclosed
WO-2006094235-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2006-09-08 WO disclosed